CAIRO — Egyptian drugmaker SEDICO and Sandoz Egypt are advancing plans to manufacture five cancer medicines locally under a technology-transfer agreement covering products with a reported import bill of $10.7 million, as the companies prepare for the project’s technical implementation phase.
SEDICO Chairman Fathy Ibrahim met Dragos Florin Toma, Head of Sandoz Operations in Egypt and Libya, to review implementation procedures and preparations for initial production.
The project follows a March 6, 2025 agreement to transfer oncology drug manufacturing technology to Egypt. The five medicines generate more than EGP 371 million in Egyptian market sales, according to figures cited in the companies’ announcement.
The partnership also includes plans to localise biosimilar medicines, although the companies have not specified the products involved or the extent of domestic manufacturing.
Local production could reduce reliance on imported finished medicines, ease foreign-currency pressures and strengthen Egypt’s pharmaceutical supply chain, depending on production capacity and imported input requirements.
Neither company disclosed the project’s investment cost, expected production volumes or commercial launch date.
Related News:
Why Global Pharmaceutical Companies Continue Expanding Manufacturing Across MENA
From Vaccine Importer to Regional Manufacturing Hub: Egypt Targets Africa’s Growing Market
Red also:
Brain Drain: Can Arab Economies Afford to Keep Losing Their Best Minds?

